PreTT is revolutionizing the treatment of cancer by using sophisticated radioligand therapies that outperform conventional techniques.
Prett has raised $540K in total funding. The most recent round was Convertible Note. The last funding was announced in February 2024.
Prett's investors include BioInnovation Institute.
Prett is headquartered in Copenhagen, Denmark.
PreTT is revolutionizing the treatment of cancer by using sophisticated radioligand therapies that outperform conventional techniques.
Prett is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prett — Funding & Investors." VCBacked, February 29, 2024, https://www.vcbacked.co/company/prett. Accessed September 30, 2026.
VCBacked. (2024). Prett — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/prett
{{cite web |title=Prett — Funding & Investors |url=https://www.vcbacked.co/company/prett |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated